First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

By sjmartinez • October 28, 2022

Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer. 2022 Oct;10(10):e005471. doi: 10.1136/jitc-2022-005471. PMID: 36302562.

Tags: Combination, drug therapy, Hematology/Oncology, Immunomodulation, immunotherapy, Investigational, Publications, Therapies

Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma

Nguyen T, Shin Y, Ruppa A, Krall AS, Pham J, Chen PC, Mirmohammadi H, Keshavarz P, Finn RS, Agopian VG, French SW, Christofk HR, Lu[...]

Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States

McCann KE, Kaklamani V, Osman N, Cannon J, Brent L, Lucia R, Li C, Duran N, Gupta S, Martin N. Treatment Patterns of Goserelin 3.6[...]

Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in Synovial Sarcoma of the Lower Extremity

Wahle CF, Newman-Hung NJ, Sakowitz S, Federman N, Singh AS, Bernthal NM, Benharash P, Wessel LE. Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in[...]